LGND

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Pharmaceutical, Health, LGND

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Retrieved on: 
Monday, April 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Epilepsy, Plasma, LGND, Conference, UMN, Seizure, Status epilepticus, Patient, Topiramate, Orphan, Pharming, Concomitant, Pharmacokinetics, University, Faculty, Safety, Poster, Food, Pharmaceutical industry

The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England.

Key Points: 
  • The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England.
  • The authors presented modeling and simulations of IV topiramate dosing based on previous studies conducted by UMN faculty in healthy research participants and patients.
  • Ligand licensed the rights to the IV formulation of topiramate from UMN and entered into a global license agreement with CURx Pharmaceuticals to further develop and commercialize the product.
  • “The availability of an injectable topiramate formulation will make it possible to ensure continuity of therapy.

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

Retrieved on: 
Wednesday, April 3, 2024
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Molluscum contagiosum, LGND, Medication, Caregiver, Partnership, Willow, Patient, Salix Pharmaceuticals, Senior, Ligand Pharmaceuticals, Therapy, Multimedia, Parent, Food, Pharmaceutical industry

Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.

Key Points: 
  • Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
  • Ligand acquired the rights to ZELSUVMI and all the assets related to the NITRICIL technology platform from Novan, Inc. in September 2023.
  • To date, Ligand has created three companies utilizing this strategy: Viking Therapeutics, Primrose Bio, and OmniAb®.
  • Pelthos is a wholly owned subsidiary of Ligand.

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, Health, LGND, Barclays, Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.
  • Management will participate in one-on-one investor meetings during the conference.
  • Investors interested in meeting with Ligand should contact their Barclays representative.

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, March 4, 2024
Professional Services, Health, Other Science, Finance, Science, Pharmaceutical, Biotechnology, Compensated emancipation, LGND, Employment, Pharmaceutical industry

The grant date for the options was March 1, 2024.

Key Points: 
  • The grant date for the options was March 1, 2024.
  • The award was granted under Ligand’s 2022 Employment Inducement Plan, as amended (the “Inducement Plan”) as an employment inducement award pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Ligand, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Ligand, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $78.70 per share, which is the closing price of Ligand’s common stock on The Nasdaq Global Market on March 1, 2024.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MRK, Research, CRL, New Drug Application, Investment, Eisai, Growth, Sale, Parent, Novin, Focal segmental glomerulosclerosis, Streptococcus, LGND, FSGS, Breakthrough therapy, BLA, AED, GAAP, Therapy, NASH, Liver, NDA, Depreciation, Breast cancer, Total, Forecasting, Perampanel, Shanda, Telecanthus, ID, Retirement, PDUFA, Vaccine, Symantec Endpoint Protection, Type 2 diabetes, Safety, VRNA, Molluscum contagiosum, F2, Acquisition, Caregiver, Merck, AASLD, FDA, Telephone, Food, Pneumonia, Income tax, Hepatology, COVID-19, Element, Patient, SPA, Pharmaceutical industry

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, General Health, Pharmaceutical, Health, Eisai, Drug development, AED, Patient, Epilepsy, LGND, AMPA, Seizure, Pharmaceutical industry

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
  • Fycompa is formulated with Captisol®, a Ligand technology.
  • Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
  • Under the terms of the agreement, Ligand is entitled to a royalty on sales of intravenous Fycompa.

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

Retrieved on: 
Friday, February 16, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Urology, Senior, ALS, Neuroscience, Immunology, Neuroinflammation, Drug development, MBA, Princeton University, Vaccine, University, Yale University, Fortress Investment Group, Infection, LGND, Harvard Medical School, Harvard Business School, Development, GSK plc, Prostate cancer, Management

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments.
  • “Rich and Karen strengthen our commercial and clinical bench, better positioning us to capitalize on this exciting period in the life sciences industry,” said Todd Davis, CEO of Ligand.
  • “These appointments are the latest in Ligand’s initiative to enhance and scale our deal capabilities by selectively adding new talent.
  • He also served as co-head of the healthcare team at Hayfin Capital Management LLP, which deployed $1.4 billion in capital over four years.

Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, General Health, Pharmaceutical, Health, LGND

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update.

Ligand To Report Third Quarter 2023 Financial Results On November 8

Retrieved on: 
Wednesday, October 25, 2023
Biotechnology, General Health, Pharmaceutical, Health, LGND, Pharmaceutical industry

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.